视网膜静脉阻塞(RVO)引起视网膜静脉扩张伴视网膜出血、黄斑水肿或缺血，在中医学属“络损暴盲”“血症”范畴。本课题组既往提出RVO中医病机为“络损积阻”，眼底血络损伤，瘀血、水湿、痰浊、气滞共“积”，并提出“祛积通络”的治疗方法。前期临床观察证实“祛积通络法”治疗RVO的有效性，但其作用机制仍不明确。现代医学认为RVO发病机制为静脉功能性调节障碍。病变部位视网膜组织缺氧可引起缺氧诱导因子1α（HIF1α）活性增加，促进血管收缩分子 (ET-1)、血管内皮生长因子(VEGF)等因子释放，进而引起血管通透性增加、血-视网膜屏障功能破坏，最终导致视网膜出血和渗出。由此可见，HIF1α/VEGF通路参与了RVO的发生发展，而“祛积通络法”如何通过HIF1α/VEGF通路干预RVO的疾病过程仍不明确。本研究以此为切入点深入研究“祛积通络法”调控HIF1α/VEGF的作用机理。为治疗RVO提供新思路。

Retinal hemorrhage, macular edema and retinal ischemia induced by retinal vein occlusion (RVO)，all named assudden visual loss and fundus hemorrhage in traditional Chinesemedicine (TCM), which is the second largest blinding retinal vessels disease. Our research group previously proposed that the pathological mechanism of RVO is "luo sun ji zu", as collateral damage retinal blood, causing bleeding, wet, phlegm and qi stagnation, and thus we proposed that RVO should be treated under the principle of “qu ji tong luo”. Our previously clinical observation has been confirmed the efficacy and safety of “qu ji tong luo” in treatment of RVO, but the mechanism remains unclear. Pathogenesis of RVO in modern medicine is the dysregulation of the vein ，due to a change of the arterial vessel wall and/or due to the hypoxic surrounding tissue.Hypoxia induces hypoxia inducible factor 1α (HIF1α) hydroxylation，it can cause the upregulation of factors such as endothelin(ET-1), vascular endothelial growth factor (VEGF) and other cytokine release，that constrict veins. They may also contribute to the impairment of the blood-retinal barrier leading to oedema and in extreme cases even to hemorrhages. It was concluded that HIF1α / VEGF pathway involved in the development of RVO. However, the intervention of “qu ji tong luo” in HIF1α / VEGF pathway involved in the development of RVO disease process remains unclear. In this study, the mechanism of “qu ji tong luo” in treatment of RVO will be studied and will proposal a new idea in treatment of RVO in TCM.